Daiichi Sankyo reports 8.8% revenue growth on drug sales

Daiichi Sankyo reported 8.8% revenue growth to 474.6bn yen in Q1 2025, with core operating profit surging 32.1% to 96.3bn yen.

The growth was driven by strong sales of cancer drug Enhertu and initial contributions from newly launched Datroway. However, profit before tax fell 4.3% due to financial balance deterioration.

The company maintained its full-year revenue forecast of 2 trillion yen and confirmed an annual dividend of 78 yen per share.